uric acid has been researched along with Supranuclear Palsy, Progressive in 7 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
Supranuclear Palsy, Progressive: A degenerative disease of the central nervous system characterized by balance difficulties; OCULAR MOTILITY DISORDERS (supranuclear ophthalmoplegia); DYSARTHRIA; swallowing difficulties; and axial DYSTONIA. Onset is usually in the fifth decade and disease progression occurs over several years. Pathologic findings include neurofibrillary degeneration and neuronal loss in the dorsal MESENCEPHALON; SUBTHALAMIC NUCLEUS; RED NUCLEUS; pallidum; dentate nucleus; and vestibular nuclei. (From Adams et al., Principles of Neurology, 6th ed, pp1076-7)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Serum uric acid (UA) levels are reported to be decreased in patients with Parkinson's disease (PD) and multiple system atrophy (MSA)." | 3.85 | Serum uric acid levels in Parkinson's disease and related disorders. ( Fujita, H; Hirata, K; Miyamoto, M; Miyamoto, T; Numao, A; Sakuta, H; Suzuki, K; Watanabe, Y, 2017) |
| "Uric acid (UA) is an important endogenous antioxidant that protects against oxidative stress, yet its exact role in neurodegeneration remains unclear." | 1.72 | Serum Uric Acid Levels in Neurodegenerative Disorders: A Cross-Sectional Study. ( Aerqin, Q; Chen, KL; Chen, SF; Dong, Q; Huang, YY; Jia, SS; Li, Q; Ou, YN; Shen, XN; Yu, JT, 2022) |
| "Uric acid is a natural antioxidant, and it has been shown that low levels of uric acid could be a risk factor for the development of PD." | 1.43 | Low serum uric acid levels in progressive supranuclear palsy. ( Cáceres-Redondo, MT; Carballo, M; Carrillo, F; Gómez-Garre, P; Huertas-Fernández, I; Jesús, S; Mir, P; Oropesa-Ruiz, JM; Vargas-Gonzalez, L, 2016) |
| "Uric acid is an oxidative stress marker." | 1.43 | Relationship between uric acid levels and progressive supranuclear palsy. ( Brody, DM; Cunningham, CR; Hall, DA; Kluger, BM; Litvan, I; Riley, DE; Shprecher, DR; Warner, S, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Aerqin, Q | 1 |
| Jia, SS | 1 |
| Shen, XN | 1 |
| Li, Q | 1 |
| Chen, KL | 1 |
| Ou, YN | 1 |
| Huang, YY | 1 |
| Dong, Q | 1 |
| Chen, SF | 1 |
| Yu, JT | 1 |
| Schirinzi, T | 1 |
| Di Lazzaro, G | 1 |
| Colona, VL | 1 |
| Imbriani, P | 1 |
| Alwardat, M | 1 |
| Sancesario, GM | 1 |
| Martorana, A | 1 |
| Pisani, A | 1 |
| Oropesa-Ruiz, JM | 1 |
| Huertas-Fernández, I | 1 |
| Jesús, S | 1 |
| Cáceres-Redondo, MT | 1 |
| Vargas-Gonzalez, L | 1 |
| Carrillo, F | 1 |
| Carballo, M | 1 |
| Gómez-Garre, P | 1 |
| Mir, P | 1 |
| Brody, DM | 1 |
| Litvan, I | 1 |
| Warner, S | 1 |
| Riley, DE | 1 |
| Hall, DA | 1 |
| Kluger, BM | 1 |
| Shprecher, DR | 1 |
| Cunningham, CR | 1 |
| Sakuta, H | 1 |
| Suzuki, K | 1 |
| Miyamoto, T | 1 |
| Miyamoto, M | 1 |
| Numao, A | 1 |
| Fujita, H | 1 |
| Watanabe, Y | 1 |
| Hirata, K | 1 |
| Constantinescu, R | 1 |
| Andreasson, U | 1 |
| Holmberg, B | 1 |
| Zetterberg, H | 1 |
| Fitzmaurice, PS | 1 |
| Ang, L | 1 |
| Guttman, M | 1 |
| Rajput, AH | 1 |
| Furukawa, Y | 1 |
| Kish, SJ | 1 |
7 other studies available for uric acid and Supranuclear Palsy, Progressive
| Article | Year |
|---|---|
Serum Uric Acid Levels in Neurodegenerative Disorders: A Cross-Sectional Study.
Topics: Alzheimer Disease; Cross-Sectional Studies; Frontotemporal Dementia; Humans; Multiple System Atrophy | 2022 |
Assessment of serum uric acid as risk factor for tauopathies.
Topics: Aged; Alzheimer Disease; Biomarkers; Female; Frontotemporal Dementia; Humans; Male; Retrospective St | 2017 |
Low serum uric acid levels in progressive supranuclear palsy.
Topics: Aged; Aged, 80 and over; Cross-Sectional Studies; Female; Humans; Male; Middle Aged; Multiple System | 2016 |
Relationship between uric acid levels and progressive supranuclear palsy.
Topics: Aged; Case-Control Studies; Cohort Studies; Female; Humans; Male; Middle Aged; Protective Factors; S | 2016 |
Serum uric acid levels in Parkinson's disease and related disorders.
Topics: Aged; Aged, 80 and over; Cross-Sectional Studies; Female; Humans; Male; Middle Aged; Multiple System | 2017 |
Serum and cerebrospinal fluid urate levels in synucleinopathies versus tauopathies.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Cross-Sectional Studies; Female; Humans; Male; Middle Ag | 2013 |
Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease.
Topics: Aged; Antioxidants; Glutathione; Humans; Multiple System Atrophy; Oxidative Stress; Parkinson Diseas | 2003 |